10:50am ET
Health and Healthcare
Is This Mesoblast Move Overrated?
Mesoblast shares more than doubled on Friday after the company provided an update on its COVID-19 treatment. Should it be taken with a grain of salt?
Chris Lange
Companies
/Healthcare
Mesoblast Ltd
$15.12
▼ $0.36 (−2.33%) today
Markets closed · 9:12pm ET
Fundamentals
Market Cap
$2.0B
Profit Margin
-47.8%
Revenue (TTM)
$120.3M
EPS (TTM)
$-0.44
52-Week Range
$13 – $22
Street Target
$37.00
About Mesoblast
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
MESO Coverage
Chris Lange 11:10am ET
Health and Healthcare
Coronavirus Stocks Seeing the Biggest Bounce Back
More and more companies are joining the fight against the coronavirus, and 24/7 Wall St. is taking a look at some of the biggest movers on the day tied to COVID-19.